This modeling study calculates individualized residual risk estimates for patients with early-stage breast cancer and assesses whether defining eligibility based on a minimum residual risk threshold could increase the reliability of clinical trial power calculations.
http://ift.tt/2DCCSUN
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
http://bit.ly/2SylJiJ
-
Publication date: June 2018 Source: Acta Biomaterialia, Volume 73 https://ift.tt/2kBbISt
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου